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that, in practical terms, the test was not
suitable in its present form for routine
cancer screening. However, the relatively
high percentage of positive tests in early
cancer indicate the possible role ofmonitoring
the patients' response to treatment, in
detecting the recurrence of tumour at an
early stage and in differential diagnosis.
Further studies are currently in hand to
investigate the possible role of the Makari
intradermal test in the monitoring ofresponse
to treatment and in the early detection of
recurrent tumour. The preliminary results
of these studies indicate that the surgical
removal of a tumour may lead to the conver-
sion of the Makari skin test from positive to
negative and during the follow-up period a
negative test may convert to positive on the
appearance of local or distant recurrence of
the tumour. It is important to stress that
these data are of a preliminary nature and
that further experience is required with more
cases and a considerably longer period of
follow-up. Nevertheless, the present data
strongly support the need for further studies
in relation to the monitoring oftreatment and
the detection of recurrent tumour.
THE VALUE OF HORMONE MEAS-
UREMENTS IN TUMOUR MANAGE-
MENT. K. D. BAGSHAWE. Department of
Medical Oncology, Charing Cross Hospital,
London
The practice of measuring hormones and
other substances produced by tumours, or by
specific organs in response to tumours, is
becoming a major occupation in the cancer
field. One of the problems is to match the
resources available to the problems which can
be defined and the distinction between
research and clinical routine operation re-
quires constant assessment. The range of
possible measurements is already very wide
and the number of patients to whom tests
are applicable is already large even though
most of the measurements do not yet relate
to the commonest malignancies.
The measurement of tumour products as
diagnostic aids is well established as a means
ofdistinguishing between neoplastic and non-
neoplastic causes for certain rare but " in-
teresting" syndromes. But some important
applications are slow to reach clinical prac-
tice, possibly because the conditions them-
selves are not regarded as "interesting" to
physicians.
Measurements may be applied to prob-
lems oftumour localization. Selective venous
sampling probably has a limited area of
application but it has a requirement for
precision in measurements which is not
readily sustained on a routine basis. Locali-
zation of tumours within the CNS can take
advantage of the blood-brain barrier and
although such methods have been available
for gonadotrophin producing tumours for the
past decade, their use has not been widespread
even though they are of substantial practical
value.
Screening operations based on tumour
products are valid for only a limited range of
tumours at the present time. Again, the
interval between developing a technology
appropriate to such a problem and putting it
into clinical operation may be very long. In
the case of uncommon tumours, screening
programmes are practicable only if carried
out on a regional or national basis.
The concept of monitoring the clinical
course of tumours with serial measurements
has been established for a limited range of
tumours and it is clear that it may sometimes
be necessary to follow more than a single
indicator substance. Different indicator
substances may provide different forms of
information and the form of information
provided by a given indicator substance may
be different for different tumours.
Nevertheless, some propositions currently
discussed in this field should perhaps be
examined critically. Do we really mean
" predictive " tests? Also, where we are
threatened by complexity we should perhaps
seek to avoid it at the outset and extract a
maximum of information from the simplest
measurements. " Multiparametric Analysis "
is not an end in itself and may be a passing
reflection of present inadequacies.
HORMONES AND THE PROSTATE.
K. GRIFFITHS. Tenovus Institute for Cancer
Research, Welsh National School ofMedicine,
Cardiff.
Regression of prostatic carcinoma in a
large proportion of patients treated by anti-
androgen therapy, either castration or oestro-
gen administration, clearly indicates the